Dr Richard Kao 高一村
Dr. Kao received his Ph. D. in Microbiology in 1999 from UBC under the supervision of Professor Julian Davies and subsequent postdoctoral training at Harvard Medical School from 1999-2001. He joined the University of Hong Kong in 2001 as a Research Assistant Professor, first in HKU-Pasture Research Center, and later in the Department of Microbiology. He is now a tenured Associate Professor in the Department of Microbiology, Li Ka Shing Faculty of Medicine, and a Member of the State Key Laboratory of Emerging Infectious Diseases at HKU.
Dr. Kao’s research focuses on the application of chemical genetics in infectious diseases. His work on SARS-associated coronavirus (SARS-CoV), which was published in Chemistry & Biology in 2004, has established the world’s first model of chemical genetics in viruses and illustrated that chemical genetic approach could be employed to probe most, if not all, druggable targets of a pathogenic virus. Dr. Kao’s team also employed similar approach to identify new druggable targets in influenza viruses and published in Nature Biotechnology in 2010 an article detailing the groundbreaking discovery of influenza A nucleoprotein as a novel druggable antiviral target and a compound which they named nucleozin as a potent antagonist of the nucleoprotein. Most recently, Dr. Kao has extended his chemical genetic studies to virulence and antibiotics resistance in bacteria and has illustrated the potential use of anti-virulence compounds to treat MRSA infections. The research results have been published in top microbiology journals Frontiers in Microbiology, mBio, and PNAS in 2016, 2017, 2018 respectively. Dr. Kao received the Innovation Academy Award from International Consortium of Prevention and Control of Infection (ICPIC) in Geneva, Switzerland in 2017.
|Awardees||Award Date||Honours / Awards / Prizes||Category|
|2019-12-01||State Scientific and Technological Progress Award (2nd Class Award) (Establishment and Application of Animal Model System for Major Human Infectious Diseases): The State Council of the People’s Republic of China, 國家科學技術進步獎(二等獎) (人類重大傳染病動物模型體系的建立及應用), 中華人民共和國國務院||Research Achievement|
|2019-05-01||Best Poster Award (1st place in the Young Investigator Category): The 32nd International Conference on Antiviral Research (ICAR 2019)||Research Achievement|
|2007-12-01||Best Poster Award "High throughput screening of chemical compounds for the treatment of osteoarthritis": 12th Ressearch Postgraduate Symposium, The University of Hong Kong||Research Achievement|
|2008-11-01||The 2008 International Association of Dental Researches/GlaxoSmithKline Innovation in Oral Care Award: GlaxoSmithKline||Research Achievement|
|2013-04-08||First prize for poster section: Screen of Small Molecule Compounds for Intervertebral Disc Degeneration by Chemical Genetics.: East meets West Symposium, Shenzhen, China, April 8-9, 2013||Research Achievement|
|2011-07-01||Faculty Outstanding Research Award: LKS Faculty of Medicine, HKU||Research Achievement|
|2015-05-01||Best Student Poster Award "Identification of a broad-spectrum inhibitor of common RNA respiratory viruses by high-throughput screening": The 28th International Conference on Antiviral Research (ICAR)||Research Achievement|
|2017-06-01||Innovation Academy Award: International Consortium on Prevention and Infection Control (ICPIC)||Research Achievement|
|Term Period||Position||Professional Societies|
|1999-present||Contributing Member||American Society for Microbiology|
Are You Missing Publications, Invited Lectures? Click Me.